达肝素抗Xa活性在重症COVID-19患者中无法预测
该探索性药代动力学研究在15例接受达肝素治疗的重症COVID-19患者中频繁监测抗Xa活性,采用非线性混合效应模型分析。线性一室模型拟合良好,但吸收和清除的个体间变异大且无法由常规临床协变量解释。蒙特卡洛模拟提示高强度达肝素使多数患者抗Xa超过预防目标,治疗强度下19%患者超治疗水平、22%低于治疗水平,故建议以抗Xa监测指导高强度达肝素。
要点
- 重症COVID-19患者达肝素吸收和清除个体间变异大,常规协变量无法解释。
- 高强度达肝素使多数患者抗Xa超过预防目标0.2-0.4 IU/mL。
- 治疗强度达肝素下19%超治疗、22%低于治疗目标0.6-1.0 IU/mL,需抗Xa监测。
核心结论
- 重症COVID-19患者达肝素抗Xa活性无法由常规临床特征预测,高强度用药时应以抗Xa监测指导。
研究设计与样本
- 探索性药代动力学研究,纳入15例接受达肝素的重症COVID-19患者,频繁时间点测量抗Xa活性,采用非线性混合效应模型分析。
主要发现
- 线性一室模型拟合良好,但达肝素吸收方差78%、清除方差34%,常规临床协变量无法解释。
- 蒙特卡洛模拟预测高强度达肝素使多数患者抗Xa活性超过预防目标0.2-0.4 IU/mL。
- 治疗强度达肝素导致19%患者抗Xa超治疗目标0.6-1.0 IU/mL,22%低于治疗目标。
关键数值与推荐
- 预防目标抗Xa活性0.2-0.4 IU/mL,治疗目标0.6-1.0 IU/mL。
临床怎么用
- 重症COVID-19患者使用高强度达肝素时,应监测抗Xa活性以指导剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Critically ill COVID-19 patients are at high risk of thromboembolic events despite routine-dosed low-molecular-weight heparin thromboprophylaxis. However, in recent randomized trials increased-intensity thromboprophylaxis seemed futile and possibly even harmful. In this explorative pharmacokinetic (PK) study we measured anti-Xa activities on frequent timepoints in 15 critically ill COVID-19 patients receiving dalteparin and performed PK analysis by nonlinear mixed-effect modelling. A linear one-compartment model with first-order kinetics provided a good fit. However, wide interindividual variation in dalteparin absorption (variance 78%) and clearance (variance 34%) was observed, unexplained by routine clinical covariates. Using the final PK model for Monte Carlo simulations, we predicted increased-intensity dalteparin to result in anti-Xa activities well over prophylactic targets (0.2-0.4 IU/mL) in the majority of patients. Therapeutic-intensity dalteparin results in supratherapeutic anti-Xa levels (target 0.6-1.0 IU/mL) in 19% of patients and subtherapeutic levels in 22%. Therefore, anti-Xa measurements should guide high-intensity dalteparin in critically ill COVID-19 patients.
引用
- van der Heijden CDCC, Ter Heine R, Kooistra EJ, et al. Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients. Br J Clin Pharmacol. 2022. PMID: 34965610. doi:10.1111/bcp.15208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。